Gene Expression Programs of Human Smooth Muscle Cells: Tissue-Specific Differentiation and Prognostic Significance in Breast Cancers by Chi, Jen-Tsan et al.
Gene Expression Programs of Human Smooth
Muscle Cells: Tissue-Specific Differentiation
and Prognostic Significance in Breast Cancers
Jen-Tsan Chi
1,2, Edwin H. Rodriguez
3, Zhen Wang
4, Dimitry S. A. Nuyten
5, Sayan Mukherjee
1,6,7, Matt van de Rijn
8,
Marc J. van de Vijver
5, Trevor Hastie
9, Patrick O. Brown
3,10*
1 The Institute for Genome Sciences and Policy, Duke University School of Medicine, Durham, North Carolina, United States of America, 2 Department of Molecular Genetics
and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America, 3 Department of Biochemistry, Stanford University School of
Medicine, Palo Alto, California, United States of America, 4 Department of Surgery, Stanford University School of Medicine, Palo Alto, California, United States of America,
5 Diagnostic Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 6 Institute of Statistics and Decision Sciences, Duke University School of
Medicine, Durham, North Carolina, United States of America, 7 Department of Computer Science, Duke University, Durham, North Carolina, United States of America,
8 Department of Pathology, Stanford University School of Medicine, Palo Alto, California, United States of America, 9 Health Research and Policy, Stanford University School
of Medicine, Palo Alto, California, United States of America,1 0Howard Hughes Medical Institute, Stanford University School of Medicine, Palo Alto, California, United States
of America
Smooth muscle is present in a wide variety of anatomical locations, such as blood vessels, various visceral organs, and
hair follicles. Contraction of smooth muscle is central to functions as diverse as peristalsis, urination, respiration, and
the maintenance of vascular tone. Despite the varied physiological roles of smooth muscle cells (SMCs), we possess
only a limited knowledge of the heterogeneity underlying their functional and anatomic specializations. As a step
toward understanding the intrinsic differences between SMCs from different anatomical locations, we used DNA
microarrays to profile global gene expression patterns in 36 SMC samples from various tissues after propagation under
defined conditions in cell culture. Significant variations were found between the cells isolated from blood vessels,
bronchi, and visceral organs. Furthermore, pervasive differences were noted within the visceral organ subgroups that
appear to reflect the distinct molecular pathways essential for organogenesis as well as those involved in organ-
specific contractile and physiological properties. Finally, we sought to understand how this diversity may contribute to
SMC-involving pathology. We found that a gene expression signature of the responses of vascular SMCs to serum
exposure is associated with a significantly poorer prognosis in human cancers, potentially linking vascular injury
response to tumor progression.
Citation: Chi JT, Rodriguez EH, Wang Z, Nuyten DSA, Mukherjee S, et al. (2007) Gene expression programs of human smooth muscle cells: tissue-specific differentiation and
prognostic significance in human breast cancers. PLoS Genet 3(9): e164. doi:10.1371/journal.pgen.0030164
Introduction
Smooth muscle (SM) is a morphologically distinct tissue
that mediates the contraction of hollow organs in the
circulatory, respiratory, gastrointestinal, and urogenital
systems. Beyond the viscera, SM is also present in a variety
of anatomical locations, such as the hair follicles, irises, and
lacrimal ducts. Smooth muscle cells (SMCs) are the main cell
type in SM tissue and have a distinct ‘‘smooth’’ appearance
because their sarcomeres, the units of contraction and force
generation, are arranged with no speciﬁc banding pattern.
SMCs share many lineage-speciﬁc markers, such as smooth
muscle a-actin (SM-a-actin), SM myosin heavy chain (SM-
MHC), SM22a, calponin, and caldesmon [1].
The differentiation of SMCs is marked by the expression of
SMC-speciﬁc lineage markers and the acquisition of the
contractile function. The discovery of common cis-acting
elements in the promoter regions of these lineage markers
has provided some insights into how SMC differentiation is
initiated and maintained (reviewed in [2,3]). The promoters
of many SMC-speciﬁc genes contain CArG [CC(A/T)6GG]
boxes or CArG box–like sequences; expression of these SMC-
speciﬁc genes is triggered by cooperative binding of the
ubiquitous serum responsive factor (SRF) and the SMC-
speciﬁc coactivator myocardin to CArG sequences [2–4].
Other transcription factors, such as MEF2B, P311 (also known
as C5orf13), MRF2 (also known as ARID5B), and GATA4 also
possess the ability to trigger SMC differentiation programs
when ectopically expressed [2,5–9], but their relative con-
tributions to the process of SMC differentiation, in compar-
ison to SRF/myocardin, are not known. Also unclear are the
temporal and spatial patterns in which these transcription
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programs.
Although all SMCs share many morphological and molec-
ular features, they carry out distinct functions in different
organs and tissues and are, therefore, likely to vary
signiﬁcantly in their contractile and mechanical properties,
hormonal control, physiological regulation, and pathological
alterations. For example, arterial SMCs must maintain proper
vascular tone to ensure adequate tissue perfusion in response
to rapid ﬂuctuations in blood volume, pressure, and tissue
oxygen demands, as well as hormonal and nervous inputs [10].
Gastrointestinal tract SMCs, in contrast, participate in the
periodic peristalsis that facilitates food passage and, there-
fore, operate at an autonomous and slower pace [10]. These
functional differences imply that signiﬁcant variations may
exist in the epigenetic programs of different SMCs. Indeed,
several studies have found heterogeneity among SMCs in the
visceral organs [11,12], within the blood vessel wall, and in
atherosclerotic lesions of the vascular wall [13–15]. But our
knowledge about the nature, extent, and molecular details of
these differences is limited.
Unlike skeletal and cardiac muscle cells, which are
terminally differentiated, mature SMCs retain their ability
to undergo large-scale, reversible phenotypic modulations in
response to various genetic and environmental inﬂuences
[16,17]. For example, the transition of vascular SMCs from the
physiological quiescent (contractile) to the pathological
activated (synthetic) state is associated with vascular injuries,
which cause migration of SMCs into the intima, where they
proliferate and produce matrix proteins [16,17]. This
phenotypic plasticity plays an important role in the patho-
genesis of human diseases, including atherosclerosis, hyper-
tension, asthma, and human cancers.
SMCs are commonly found in cancers as components of
blood vessel walls. Blood vessels in tumors are often
abnormal—they can be greatly enlarged, tortuous, and
‘‘leaky’’—and the component SMCs often have abnormal
morphology and sometimes fail to express the appropriate
SMC differentiation marker genes [18]. These structural
abnormalities contribute to the spatial and temporal hetero-
geneity in tumor blood ﬂow, resulting in elevation of tumor
interstitial pressure, hypoxia, and acidosis [19,20]. These
hostile tumor microenvironments play a major role in tumor
progression and treatment failure, but it has been challenging
to quantify and dissect these factors [19].
In this study, we investigated molecular details of SMC
heterogeneity by systemically examining the global expres-
sion proﬁles of puriﬁed, cultured SMCs isolated from various
organs and anatomical structures. We found pervasive
differences among SMCs from different organs and tissues.
An investigation of the gene expression program induced in
vascular SMCs by serum exposure, an ex vivo model of
vascular injury, identiﬁed a signature that proved to be
signiﬁcantly associated with prognosis in various human
cancers. This observation suggests a possible link between
blood vessel injury and tumor progression and treatment
response in cancer patients.
Materials and Methods
Cell Culture
SMCs isolated from bronchus, uterus, cervix, different
blood vessels, urinary bladder, ureters, urethra, and pulmo-
nary artery were obtained from Cambrex. The cells were
thawed and propagated in SmGM-2 media (Cambrex),
according to the manufacturer’s instructions, and cultured
under standard conditions (5% FCS with ﬁbroblast growth
factors, steroids, and epidermal growth factors) or low-
growth conditions (1% FCS with no growth factors). Once
the cells reached 60%–70% conﬂuency, mRNA was harvested
using the FastTrack mRNA Isolation Kit (Invitrogen). The
cells were harvested between the third and ﬁfth passages,
after approximately 10–15 generations in culture. We
conﬁrmed that each cultured cell population consisted of
SMCs, free of epithelial, endothelial, or Schwann cells, by
immunoﬂuorescent staining, using antibodies against cyto-
keratins (C-11, Sigma), desmin (Ab-1, NeoMarkers), glial
ﬁbrillary acid protein (ab-7, NeoMarkers), vimentin (V9,
Sigma), and CD31 (Ab-2, Neomarkers or Pharmingen).
cDNA Microarray Procedure and Data Analysis
Human cDNA microarray production (from Stanford
Functional Genomic Facility) and hybridization were per-
formed as previously described [21]. mRNA was puriﬁed using
the FastTrack mRNA Isolation Kit (Invitrogen), according to
the manufacturer’s instructions. Human common RNA
reference (Strategene) was used in all experiments as the
standard reference. Two micrograms of all RNA samples were
ﬂuorescently labeled with amine-reactive dyes after reverse
transcription. SMC samples were labeled with Cy5, and
common reference samples were labeled with Cy3. The Cy5-
and Cy3-labeled samples were mixed together and heated at
95 8C for 3 min before hybridizing with printed cDNA
microarrays for 12–16 h in a 65 8C water bath in sealed
cassettes. Following hybridization, microarrays were washed
and dried prior to high-resolution scan on a GenePix 4000B
Array Scanner (Axon). Each element was located and
analyzed using the GenePix Pro 5.0 software package (Axon).
These data were submitted to the Stanford Microarray
Database (SMD) for further analysis. Data were normalized
globally per array, such that the average LogRatio was 0 after
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Author Summary
It has been estimated that the human body contains approximately
200–400 distinct cell types. These estimates are largely based on the
morphological characteristics of cells and have yielded, among
many others, the category of smooth muscle cells, which have a
distinct appearance and are present in a wide variety of tissues. By
using DNA microarrays to interrogate the gene expression of
anatomically varying smooth muscle cells, we were able to
accurately tease apart many of the distinct cell subtypes that are
classically categorized as smooth muscle cells. Remarkably, genes
expressed by these newly identified, distinct subtypes corroborate
many of their known biological properties and give clues about their
susceptibility to specific disease states, retained developmental
programs, and potential drugable targets. Additionally, from a
smooth muscle cell model of vascular injury, we were able to extract
a gene expression signature that provides prognostic information
for human breast cancers. Of particular interest for modeling tumor
progression was the finding that this gene expression signature was
associated with tumor hypoxia. This study adds much to our ever-
growing depth of understanding of cellular diversity and the
contributions of this diversity to normal physiology and disease.normalization. Hierarchical clustering with weighted average
linkage clustering was performed after indicated data ﬁlter-
ing based on spot quality and variations in signal intensity as
described [22].
Results
Genome-Wide Analysis of Smooth Muscle Cell
Heterogeneity
We established 39 primary SMC cultures from 18 different
anatomic locations under identical culture conditions (see
Materials and Methods). The 36 primary SMCs included cells
puriﬁed from ﬁve different arteries (aorta, coronary artery,
pulmonary artery, iliac artery, and umbilical artery) and four
different veins (hepatic, renal, saphenous, and popliteal veins)
as well as SMCs isolated from the bronchus, gastrointestinal
tract (colon), female genital tract (uterus and cervix), and
urinary tract (urinary bladder, ureter, and urethra) (detailed
information on all SMC samples is available on the
supplemental Web site). All SMCs displayed a uniform
spindle shape in culture and were positive for SMC-a-actin.
All SMC samples were also stained for endothelial cell and
epithelial cell markers (CD31 and pan-keratins, respectively)
to rule out contamination from other cell lineages. Three
SMC samples (one from bronchus, one from colon, and one
from saphenous vein) were excluded from further analyses
due to signiﬁcant contamination (.10%) from other cell
types. To investigate how the gene expression patterns in
diverse SMCs respond to a common physiological stimulus, 24
of the 36 remaining SMC samples were also cultured in low-
growth media (basal media [SMBM] supplemented with only
1% serum and no additional growth factors).
The global expression patterns of all 60 samples (36 SMCs
grown in standard-growth and 24 SMCs grown in low-growth
conditions) were analyzed using cDNA microarrays, contain-
ing approximately 42,000 elements, representing 27,291
unique Unigene clusters (Build number 173, released on 28
July 2004) to generate a total of 2.6 million gene expression
measurements; these measurements cover a signiﬁcant
portion of known genes. The expression data were submitted
to the SMD and globally normalized so that the average
LogRatio was 0 after normalization [23]. We further analyzed
the 16,352 gene elements that were expressed in at least 80%
of the SMC samples. These elements were identiﬁed by
looking for elements with Cy5 signal more than 2.5-fold
above local background. Unsupervised hierarchical clustering
of the gene expression patterns of all 60 samples produced
consistent groupings of most SMCs according to their sites of
origin (Figure 1A), suggesting that SMCs from different
anatomic locations have distinct expression patterns that
persist with serial passage in vitro. The 60 SMC samples were
clustered into two large, distinct branches: a ‘‘vascular’’
branch contained all the cells isolated from blood vessels and
airways, and a ‘‘visceral’’ branch contained all the cells
isolated from visceral organs (colon, urinary tract, uterus, and
cervix) (Figure 1A). Within the visceral branch, there were
three distinct subbranches; one containing all the SMCs from
the urinary tract (including ureter, urinary bladder, and
urethra), one with female reproductive tract SMCs (uterus
and cervix), and one subbranch of colon SMCs (Figure 1A).
This grouping pattern is not related to the age of the donor
since there was no statistically signiﬁcant difference in the
donor ages between the ‘‘vascular’’ and ‘‘visceral’’ SMC
groups (Table S2). To rule out the contribution of gender
in sample clustering, we performed an unsupervised analysis
on the 24 SMC samples from female donors (under high-
growth conditions) and were able to generate a similar
grouping pattern (detailed in the Web supplement). Interest-
ingly, culturing SMCs in low-growth conditions had only a
relatively modest effect on the clustering pattern (Figure 1A).
The clustering of all SMC samples into either the vascular or
visceral SMC groups was driven mainly by two large clusters
of genes, to which we will refer as the vascular and visceral
gene clusters (Figure 1B).
The HOX gene family encodes a family of evolutionarily
conserved transcription factors known to be involved in
determining positional identity and tissue specialization in
animals [24]. Previously, we found that ﬁbroblasts could be
clustered by anatomic location based on their patterns of
expression of a small number of HOX genes [25]. To assess the
possible role of HOX genes in SMC topographic differ-
entiation, we identiﬁed 63 genes encoding homeodomain
transcription factors that had well-measured expression in
these experiments. Hierarchical clustering of the cultured
SMCs based solely on their patterns of expression of these 63
homeodomain genes recapitulated grouping of the SMCs
according to their site of origin (Figure 1C, the dendrogram
labeled as ‘‘all’’ is identical to the dendrogram from Figure
1B); the vascular and visceral groupings were also retained.
This homeodomain gene set also successfully separated the
visceral SMCs into the three previously deﬁned subbranches:
urinary tract, female reproductive tract, and colon, suggest-
ing that this family of transcription factors may play an
important role in specifying the distinct developmental
programs of the SMCs.
Genes Expressed Preferentially in Vascular and Bronchial
Smooth Muscle
To determine the differences in molecular features
between vascular and visceral SMCs, we used a supervised
method, Signiﬁcance Analysis of Microarrays (SAM) [26], to
identify 3,276 unique genes (represented by 4,870 array
elements), whose expression varied consistently between the
31 vascular SMCs and the 29 visceral SMCs, with a false
discovery rate (FDR) of less than 0.001%. All SMC samples
were then arranged by hierarchical clustering, based on
expression of these 3,276 unique genes (Figure 2A), to yield a
clustering pattern almost identical to the unsupervised
sample groupings (Figure 1A).
Among genes preferentially expressed in vascular SMCs
were many that encode proteins in the transforming growth
factor-b (TGF-b) pathway, which affects differentiation,
proliferation, migration, and the induction of extracellular
matrix (ECM) production, as well as genes responsible for
ECM biosynthesis and modiﬁcation [27–30]. The high
expression of these genes in the vascular SMCs contributes
to their ability to maintain the tensile strength of blood
vessels through the synthesis and deposition of connective
tissue proteins [31]. Vascular SMCs also expressed many genes
involved in inﬂammatory responses, suggesting an intrinsic
ability of vascular SMCs to communicate with inﬂammatory
cells to initiate and modulate the chronic inﬂammatory and
ﬁbroproliferative processes underlying atherosclerosis and
other vascular diseases [32].
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encoding proteins known to be involved in reciprocal
signaling with adjacent endothelial cells and in the eicosa-
noid/prostaglandin signaling pathways that regulate vascular
tone (Figure 2B, gene names shown in purple). A more
extensive discussion of these genes appears in the supple-
mental text in the supplemental Web site.
To further search for systematic differences in molecular
pathways between the two broad divisions of SMCs (vascular
and visceral), we employed a gene-set enrichment analysis
[33] that evaluated differential expression of predeﬁned sets
of functionally related genes within our dataset. A running
statistic (the Kolmogorov-Smirnof or KS statistic) determines
how highly the coordinate expression of each gene set ranks.
This statistical tool provides a systematic approach to
objectively identify gene sets with functional themes that
can be correlated with biological phenotypes. We tested 410
gene sets (compiled from previously published expression
studies of common cellular pathways and pathological states
and curated by Biocarta [34] and KEGG [35]) for their
enrichment in vascular or visceral SMCs. Gene sets that
achieved enrichment greater than expected by chance alone
were identiﬁed by permuting the vascular and visceral SMC
sample labels 1,000 times. Of the ten pathway-speciﬁc gene
sets with the highest normalized enrichment scores (the
normalized enrichment scores for all 410 pathways are
detailed in the web supplement), eight were enriched in
vascular SMCs and two were enriched in visceral SMCs
(Figure 2C). The gene sets showing enrichment in vascular
SMCs were associated with inﬂammation, tumor necrosis
factor (TNF), TGF-b, interleukin 1 receptor (IL1R), and
chemokine receptor pathways. Interestingly, genes of the HIF
pathway [such as VEGFA,e n d o t h e l i n - 1( EDN1), lactate
dehydrogenase A (LDHA), and HIF1A] were also enriched
among genes differentially expressed in vascular SMCs. To
test whether an expression signature of the hypoxia response
Figure 1. Diversity of SMC Gene Expression Patterns
(A) Gene expression patterns of cultured SMCs organized by unsupervised hierarchical clustering. The global gene expression patterns of 60 cultured
SMCs were sorted based on similarity by hierarchical clustering. Approximately 6,166 gene elements (representing 5,236 distinct genes) were selected
from the total dataset, based on variations in expression relative to the mean expression level across all samples greater than 3-fold in at least two cell
samples. The anatomic origins of each SMC culture are indicated and color coded. The apparent order in the grouping of SMC gene expression patterns
is indicated in this dendrogram.
(B) Overview of gene expression patterns of all SMC samples. The variations in gene expression described in Figure1A are shown in matrix format. The
scale extends from 0.25- to 4-fold variation from the mean across all samples ( 2t oþ2 in log2 scale). Gray represents missing data. The gene clusters
characteristic of vascular/bronchial, visceral SMCs, and proliferation are indicated on the right. Complete data can be found on the supplementary Web
site and SMD.
(C) Gene expression patterns of cultured SMCs organized by unsupervised hierarchical clustering based on expression of 63 homeodomain genes. The
dendrogram generated by 63 hox genes (labeled as ‘‘hox’’) is compared with the dendrogram generated by all genes (labeled as ‘‘all’’).
doi:10.1371/journal.pgen.0030164.g001
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previously obtained hypoxia-response gene signature [36] to
analyze the SMC expression dataset. When all 60 SMC
samples were arranged by hierarchical clustering based on
the expression levels of all 71 genes in the common hypoxia-
response gene list [36], most vascular SMCs clustered
separately from visceral SMCs as a result of their relatively
high expression of HIF1A and the common hypoxia-response
genes (Figure 2D). This concordant expression of HIF1A and
the other hypoxia-response genes was also observed in renal
proximal tubule epithelial cells and ovarian cancers, and high
HIF1A transcript levels were associated with a vigorous
hypoxia response [36]. Interestingly, hypoxia of the blood
vessel wall has been linked to the development of athero-
sclerosis [37,38], so the differential expression of this hypoxia-
response gene set and its inﬂuence on the transcriptional
Figure 2. Vascular and Visceral SMC Gene Expression Programs
(A) Identification of vascular and visceral SMC gene expression programs. Dendrogram representing the result of hierarchical clustering of SMCs, based
on the similarities in their pattern of expression of the genes selected by a two class SAM test.
(B) Features of vascular and visceral SMC gene expression programs. The expression of 2,338 vascular SMC-specific genes and 2,462 visceral SMC-
specific genes selected by SAM analysis is shown here. Genes involved in TGF-b signaling (red), ECM components and biosynthesis (orange),
inflammatory response (blue), and endothelial cell interaction (purple) are labeled by the indicated colors. Complete data can be found on the
supplementary Web site and SMD.
(C) Comparison of pathway activity in vascular and visceral SMCs by Gene Set Enrichment Analysis. The top ten molecular pathways ranked by
normalized enrichment scores enriched specifically in vascular (purple, positive) or visceral (green, negative) SMC samples are shown.
(D) The expression of a common hypoxia gene signature among all SMCs. The expression values of 71 genes constituting the common hypoxia
response in the vascular versus visceral SMCs are shown.
(E) Confirmation of specific expression of CTGF, LMO2, and HDAC9 in vascular SMCs; of specific expression of MITF, MYLK, and NRP2 in visceral SMCs;
and of control gene GAPDH in all SMCs with RT-PCR.
doi:10.1371/journal.pgen.0030164.g002
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the pathogenesis of atherosclerosis.
Genes Expressed Preferentially in All Visceral Smooth
Muscle
All SMCs isolated from visceral organs share features of the
gene expression programs that distinguish them from
vascular SMCs (Figure 2B, gene names shown in black),
notably including several transcription factors involved in the
establishment and maintenance of SMC differentiation
(MRF2 (also known as ARID5B) [9], PBX1, HoxA10, and
HoxA11 [6,39,40]). Disruption of the PBX1 gene in mice leads
to a general hypotrophy of many visceral organs, yet no
vascular abnormalities are noted [40], in accordance with its
visceral SMC-speciﬁc expression. Visceral SMCs also prefer-
entially expressed microphthalmia-associated transcription
factor (MITF). In addition to its expression in melanocytes
and mast cells [41], MITF has been shown to be present in
uterus and other tissues [42]. MITF can inhibit the activities
of transforming growth factors (TGF-b) by binding to Smad3,
a key signaling component of the TGF-b pathways [43]. High
levels of MITF may play a role in modulating the activity of
the TGF-b pathway in visceral SMCs (Figure 2B), thereby
promoting a functional partitioning of visceral from vascular
SMCs.
Visceral SMCs also preferentially expressed Histamine N-
methyltransferase (HNMT), an essential enzyme that regu-
lates histamine levels in tissues by catalyzing its inactivation
by N-methylation [44] (Figure 2B). Histamine is a strong
agonist of smooth muscle contraction [45] with an important
role in maintenance of contractile tone. The importance of
HNMT in regulating histamine signaling is illustrated by the
increased incidence of bronchial asthma that is seen in
patients with certain HNMT polymorphisms [46]. Preferential
expression of HNMT in all visceral SMCs suggests a strong,
intrinsic ability of these cells to catalyze the local degradation
of histamine. The difference in HNMT levels between visceral
and bronchial/vascular SMCs may be at the root of the clinical
observation that the respiratory and vascular system re-
sponses (hypotension, tachycardia, and bronchoconstriction)
are more prominent than those of the visceral organs
(urinary or digestive tract) when circulating histamine levels
are high as a result of systemic anaphylaxes [47]. We have
further conﬁrmed the vascular- and visceral-speciﬁc expres-
sion in these SMC cells with reverse transcriptase PCR (RT-
PCR) (Fig 2E).
Expression Profiles of Bronchial, Arterial, and Venous SMCs
In an unsupervised analysis (Figure 1A), SMCs isolated
from arteries, veins, and bronchi did not segregate according
to their tissue types of origin, unlike their endothelial cell
counterparts, whose clustering pattern based on global gene
expression closely reﬂected their arterial or venous origins
[21]. Taken together, these results show that endothelial cells
have stronger intrinsic arterial versus venous gene expression
programs than their SMC counterparts, suggesting that
endothelial cells, instead of SMCs, are the main cellular
determinants for the arterial or venous identity [48]. To
further explore this concept, we used a supervised analysis to
determine whether and how the diversity in developmental
origins, structures, and functions among bronchi, arteries,
and veins were associated with identiﬁable, tissue-speciﬁc
molecular features. Using a multi-class SAM analysis, at an
FDR of 0.1%, we identiﬁed a set of 1,037 genes differentially
expressed among SMCs isolated from these three distinct
kinds of tissues. The distinct patterns of expression of these
genes allow the hierarchical clustering of vascular SMC
samples into three separate groups largely based on tissue
of origin (bronchus, vein, or artery) (Figure 3A). Gene clusters
showing arterial- (red), venous- (blue), and bronchial-speciﬁc
(light blue) expression are expanded and shown (Figure 3B).
Several arterial SMCs were grouped in the venous branch,
even with this set of selected genes (Figure 3A and 3B).
Interactions between the immune system and vascular
SMCs play important roles in the pathogenesis of many
vascular diseases. Arterial SMCs, in particular, express a large
set of genes that mediate these interactions—such as
cytokines/chemokines (IL6, CCL8, CCL7, CCL2, CXCL1,
CXCL2, CXCL3, and CXCL6), complement pathway (comple-
ment factor B [CFB]), and surface receptor (ICAM1) (Figure
3B)—suggesting that vascular SMCs may themselves mediate
recruitment of immune cells to the vascular walls. Perhaps
these speciﬁc molecular interactions between the immune
system and arterial SMCs may contribute to the preferential
occurrence of atherosclerosis in arteries.
SMC samples derived from lung tissue (pulmonary artery
and bronchus) expressed a common set of genes (Figure 3C),
notably including the genes encoding FOXP1, a transcrip-
tional repressor expressed in lung mesenchyme that modu-
lates gene expression in lung tissue [49], and endothelin
receptor A (EDNRA), the high-afﬁnity receptor for EDN1, a
peptide hormone that stimulates vasoconstriction and pro-
liferation of SMCs [50].
Gene Expression Patterns of Visceral Organ SMCs
When the global gene expression patterns of cultured
SMCs isolated from urinary tract (ureter, urinary bladder,
and urethra), colon, and the female reproductive tract (uterus
and cervix) were hierarchically clustered, they consistently
grouped into three distinct subbranches according to their
anatomic origin (Figure 1A). To identify genes expressed
differentially among the three subgroups of visceral SMCs, a
multi-class SAM was performed. The analysis identiﬁed 3,879
genes (represented by 4,889 array elements) with an FDR of
1.5%. We then performed a hierarchical cluster analysis of all
visceral SMCs based on expression of these genes (Figure 4A).
The distinct gene expression patterns of SMCs from different
visceral organs are likely to be related to the characteristic
differences in the developmental fates and physiological
functions unique to visceral organs.
For example, colonic SMCs expressed ﬁbrillin-2 (Figure
4B), a component of connective tissue microﬁbrils that is
involved in elastic ﬁber assembly, organization of the ECM
(which allows it to inﬂuence the physical properties of
connective tissue), and regulation of growth factor signaling
(which allows it to also direct a broad spectrum of cellular
activities) [51]. The urinary tract gene cluster contained
several genes that are known to be essential for the develop-
ment of the renal and urinary tract systems, including the
leukemia inhibitory factor (LIF) and oncostatin M (OSM)
receptors (LIF receptor, OSM receptor, and IL6ST [52]) and
their downstream signaling molecule SOCS3 (Figure 4C). The
activation of these receptors by their respective ligands (LIF
and OSM, two members of the IL6 family) induces the
PLoS Genetics | www.plosgenetics.org September 2007 | Volume 3 | Issue 9 | e164 1775
Expression Programs of Human Smooth Muscle CellsFigure 3. Artery, Vein, and Bronchial SMC-Specific Gene Expression Program
(A, B) Artery-, vein-, and bronchus-specific genes were identified by a multi-class SAM analysis. The names of select vein-specific genes (blue bar),
bronchus-specific genes (light blue bar), and artery-specific genes (red bar) are shown and expanded in (B). Complete data can be found on the
supplementary Web site and SMD.
(C) Features of a gene cluster with expression in lung tissues. Pulmonary artery clusters are marked by the black horizontal bar and bronchus clusters are
marked by the light blue horizontal bar. Selected genes are shown.
doi:10.1371/journal.pgen.0030164.g003
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thelium in the urinary tract [53,54]. Inactivation of IL6ST, a
component of the functional receptors for LIF and OSM,
leads to developmental defects in the kidney [53,54]. Bone
morphogenic protein 4 (BMP4) was also selectively expressed
by SMCs isolated from urinary tract structures (Figure 4C).
This protein has an essential role in the inductive signal
between the endodermal epithelium and mesenchyme de-
rived from splanchnic mesoderm [55], and BMP4 haplodeﬁ-
ciency can lead to renal defects [56]. It appears, therefore,
that expression of several of the genes involved in key
inductive signals during urinary tract development persists
beyond embryogenesis and remains a feature of locally
specialized SMCs, allowing these cells to selectively detect
and respond to local induction cues.
We have also found components of a regulatory network
consisting of FOXF1, vascular cell adhesion molecule-1
(VCAM1), and hepatocyte growth factor (HGF) selectively
expressed in colon and urinary tract SMCs (Figure 4D).
FOXF1 is a transcription factor essential for development of
visceral splanchnic mesenchyme [57,58]. Haplodeﬁciency of
FOXF1 abolishes the expression of VCAM1 and HGF and
leads to structural defects in the gallbladder and other
visceral organs [59]. The simultaneous presence of FOXF1,
VCAM1, and HGF in colon and urinary tract SMC gene
clusters (Figure 4D) suggests that their regulatory relationship
may be preserved in these SMCs.
For hormones that reach their distant target tissues
through systemic circulation, an important determinant of
the speciﬁcity of their biological effects is the differential
expression of hormone receptor genes in target tissue cells.
Oxytocin, the neuropeptide responsible for triggering ute-
rine contractions and lactation [60], is no exception. Oxy-
tocin receptor is present in many organs, suggesting roles in a
variety of biological processes [61,62]. In the present study, we
have found that oxytocin receptor is expressed speciﬁcally in
uterus SMCs but none of the other SMCs examined in this
study (Figure 4E). This uterus-speciﬁc expression can help to
explain the unique sensitivity of the uterus to oxytocin during
parturition and the clinical usefulness of oxytocin agonists or
antagonists, respectively, to induce or prevent labor.
Uterus SMCs also have especially high expression levels of
many genes that encode the contractile machinery of SMCs,
including tropomyosin 1 and 2, calponin, caldesmon 1, SM-a-
actin, MYH9 myosin, heavy and light chain polypeptide, and
phospholamban (Figure 4E). These genes are widely consid-
ered as cell-type lineage markers for all SMCs; indeed,
expression of SM-a-actin was used in this study as a criterion
to insure that all cells in our cultured samples were SMCs.
The unusually high level of expression of these proteins in
uterine SMCs, however, suggests not only that there are
quantitative differences in the force-generating apparatus
and the contractile capacities among different SMCs but also
that these differences may reﬂect the distinct mechanical
requirements of each SM cell type. The uterus, for example,
must generate enough force and pressure within a short time
frame to deliver the fetus through the birth canal during
labor. The SMCs of the adjacent cervix, which relaxes and
expands during parturition, express the genes encoding the
contractile apparatus at levels signiﬁcantly lower than that in
the uterine SMCs (Figure 4E), despite the overall similarity in
the gene expression patterns of uterine and cervical SMCs
(Figures 1A and 2B).
Gene Expression Programs Induced by Serum Stimulation
of Vascular SMCs Are Linked to Prognosis in Some Human
Cancers
SMCs can undergo remarkable phenotypic modulations in
response to environmental stimuli, and the association
between the occurrence of these transitions and the onset
of various human diseases is well established. An example of
this phenomenon is the phenotypic change from the
quiescent ‘‘contractile’’ to the activated ‘‘synthetic’’ state of
vascular SMCs associated with serum exposure. Vascular
SMCs are usually shielded from the circulating blood by a
layer of overlying endothelial cells. When the integrity of the
endothelial cell barrier is compromised, vascular SMCs come
into direct contact with all of the components of blood,
including serum constituents generated by activation of the
coagulation cascade. Although serum is a complex and not
fully deﬁned mixture, exposure to serum, the soluble fraction
of coagulated blood, represents a physiologically relevant
stimulus associated with various forms of vascular injury.
Scenarios that can lead to the exposure of vascular SMCs to
serum include inﬂammation; injury; the development of
faulty, leaky blood vessels in tumors [63]; and acute
endothelial damage from balloon angioplasty [64].
We investigated the response to serum as a simple,
controlled, ex vivo model of the temporal response of
vascular SMCs to vascular injury induced by serum exposure.
Coronary artery SMCs were ﬁrst placed under replicative
quiescence in DMEM media with 0.1% serum for 48 h, then
exposed to fully supplemented media, DMEM with 10%
serum [65], and the ensuing temporal program of gene
expression was followed by analyzing samples at 1, 3, 6, 12,
and 24 h with DNA microarrays. We derived the SMC serum
responses by performing zero-transformation against three
time zero samples. A comparison of the SMC serum response
to a previously deﬁned ﬁbroblast serum response [66] (Figure
S1) revealed that there was a high degree of similarity
between the serum responses of these two cell types and that
several gene clusters share similar induction kinetics (clusters
1, 3, and 5 in Figure S1). There were also some distinct
features associated with each cell type. For example, several
genes induced by serum only in SMCs were implicated in
atherosclerosis. A cluster of genes involved in cholesterol
biogenesis (cluster 7) was noted to be repressed by serum
exposure in ﬁbroblasts but not SMCs [66].
To systemically deﬁne a gene signature reﬂecting the serum
response of vascular SMCs, we used SAM to identify 534
unique genes (653 gene elements), with an FDR of 1%, that
distinguish three serum-starved vascular SMC samples from
ﬁve serum-exposed vascular SMC samples (Figure 5A). All the
selected genes were induced upon serum exposure. The SMC
serum-response signature shares relatively few features with
previously deﬁned gene expression signatures of cellular
responses to physiological stimuli: 39 genes in common with
the ﬁbroblast serum-response signature [66], 19 genes in
common with the proliferation signature [67], and 22 genes in
common with the epithelial hypoxia response signature [36].
To investigate the possible contribution of the vascular
SMC serum-response program in the progression and
phenotypes of human cancers, we deﬁned a quantitative
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averaging the relative gene expression levels (logarithmic
scale) of the 534 genes in the vascular SMC serum-response
gene signature. Calculating the average expression level
allowed a quantitative and unbiased determination of the
activity of the SMC serum-response program, which was likely
to be more stable than the expression of any particular genes
in the expression program. This approach also provided a
metric that could be applied to tumor samples based on their
gene expression patterns to gauge the degree to which a
program similar to the vascular SMC serum response was
active in each tumor. We ﬁrst evaluated the vascular SMC
serum-response signature in a Stanford breast cancer study
representing expression proﬁles of 85 samples containing
normal breast tissues, ﬁbroadenomas, and 78 locally advanced
breast cancers with associated extensive clinical and molec-
ular data [68]. Among the vascular SMC serum-response
genes, 68 genes were well measured in 80% of the breast
samples and used to determine their SMC serum scores
(Figure 5B). When we split all ductal adenocarcinoma samples
based on their SMC score, 41 samples had an SMC score lower
than zero while 44 samples had an SMC score higher than
zero (Figure 5B). To investigate the signiﬁcance of this
separation, we compared samples with respect to overall and
relapse-free survival. The patients with high SMC scores had
signiﬁcantly lower overall survival (p ¼ 0.0063) and relapse-
free survival (p ¼ 0.0007) based on a Cox-regression model
(Figure 5C).
To assess the consistency and prognostic signiﬁcance of the
SMC serum-response signature in an independent set of
Figure 4. Colon-, Urinary Tract-, and Uterus-Specific Gene Expression programs
(A–D) Colon-, urinary tract-, cervix- and uterus-specific gene expression identified by a multi-class SAM analysis are shown in (A) and names of select
genes are expanded in (B–E). Named genes are colon specific (B, brown bar), urinary tract specific (C, orange bar), urinary/colon specific (D, black bar)
and uterus specific (E, pink bar). Complete data can be found on the supplementary Web site and SMD.
doi:10.1371/journal.pgen.0030164.g004
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Expression Programs of Human Smooth Muscle CellsFigure 5. Analysis of Vascular SMC Serum Response and Its Prognostic Significance in Human Cancers
(A, B) Expression of the 653 genes in the SMC serum-response signature in coronary SMCs before (green) and after (red) serum exposure at indicated
time points (A). The SMC serum-response scores of the Stanford breast tumor collection (B) were calculated based on the average expression values of
the serum-response signature genes. The tumors were separated based on whether SMC serum-response scores were positive (red, right) or negative
(green, left).
(C, D) With the threshold value of the SMC serum-response signature set at zero for classification of patients into high (red) and low (green) SMC serum-
response groups, the Kaplan-Meier analysis shows significant differences in survival and time to recurrence between the two groups of samples in the
Stanford (C) and NKI (D) breast cancer datasets.
(E) Correlation of the quantitative and continuous SMC serum-response score (x-axis) of each tumor sample (black circle) in the NKI breast cancer
dataset versus the (log) relative risk (y-axis) of mortality.
(F) Scatter plots showing the relationship between the wound-response [66], hypoxia-response [36], proliferation [67], and SMC serum-response
signatures. Each point in the scatter plots represents a single one of the 295 tumors analyzed in the NKI dataset. The overall correlation between each
pair of expression signatures across this set of 295 samples is indicated in each panel.
doi:10.1371/journal.pgen.0030164.g005
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the Netherlands Cancer Institute (NKI), which consisted of
295 early-stage breast cancer samples (stage I and II). Of the
653 genes that comprised the vascular SMC serum-response
gene cluster in our microarray dataset, 640 were also
represented in the microarrays used in the NKI study. The
expression of these 640 genes in the 295 breast cancer
samples allowed the separation of all the tumors into two
distinct groups based on the SMC serum-response score
(Figure 5D). Tumors in the high SMC serum-response group
were associated with poorer overall survival (p ¼ 0.001)
(Figure 5C) than those in the low SMC serum-response group,
conﬁrming the prognostic value of the serum-response gene
expression program of vascular SMCs. While thresholding the
score at zero produced a striking discrimination of tumor
phenotypes, this cut-off point was somewhat arbitrary. To
investigate whether an alternative model based on the SMC
serum-response signature might improve predictive power,
we ﬁt a multivariate Cox model including the SMC serum
score in a quantitative form. These curves estimated the
differential contribution of the SMC serum score to the (log)
relative risk in a continuous fashion (Figure 5E). The results
showed a strong positive correlation between the clinical risks
with the SMC scores over a wide range of SMC serum scores
in which most of the data occurred. Similarly, this SMC
serum-response signature was associated with signiﬁcantly
shorter survival in a separate study of ovarian cancers,
separating 72 patients with advanced ovarian cancer into
groups with markedly different clinical outcomes (M. E.
Schaner, personal communication).
Previous studies have shown that gene expression signa-
tures related to cellular proliferation [67], a ﬁbroblast serum
response (wound) [66] and a hypoxia response [36] identiﬁed
breast cancer patients with signiﬁcantly poorer survival.
Although there is rather little overlap in the genes compris-
ing the gene expression signatures of these three distinct
biological processes, their efﬁcacy in providing clinical
insights in the same set of tumor samples raises the possibility
that they may be related. To investigate their potential
relationship, we calculated the scores of 295 NKI breast
tumors based on the four different gene signatures (Figure
5F). Then we calculated the pair-wise correlation of signature
scores to determine their potential relationship. As reported
previously, the hypoxia score is only weakly correlated with
the ﬁbroblast wound-response (corr ¼ 0.11) or proliferation
scores (corr ¼ 0.215) [36]. In contrast, the SMC Serum score
was highly correlated with the hypoxia response score (corr¼
0.601). This result suggests that the breast cancers with an
activated hypoxia response also tend to have an activated
program related to the vascular SMC serum response. The
vascular SMC serum response might reﬂect vascular injury;
perhaps the hypoxia response and SMC serum response are
both elevated in a subset of breast tumors with vascular
abnormalities and poor tumor oxygenation. A similar
correlation between the hypoxia and SMC serum-response
signatures was observed among the breast cancer samples
characterized at Stanford (Figure S2). Interestingly, although
the ﬁbroblast wound-response signature was also elicited by
ex vivo serum exposure, there was only a weak correlation
between the ﬁbroblast wound-response score and SMC
serum-response score in these cancers (corr ¼ 0.268).
To test whether the vascular SMC serum response contrib-
utes anything new and useful to clinical decision making or
complements previously established prognostic factors, we
evaluated it in a multivariate Cox model that included other
established prognostic and clinical factors in the NKI breast
cancer dataset. Although it had signiﬁcant prognostic value
by itself, the vascular SMC serum-response signature con-
tributed little additional predictive power when chemo-
therapy, ER status, tumor size, grade, angioinvasion, and age
were included in the predictive model. Therefore, the
prognostic information represented by the vascular SMC
serum-response signature was already contained in, and
perhaps functionally linked to, the classical prognostic factors
(Table S1).
Discussion
It has been claimed that there are approximately 200–400
cell types in the human body [69]. The aims of this study were
to begin to examine how many distinct cell types are truly
encompassed by the moniker ‘‘smooth muscle cell’’ by
systematically comparing gene expression patterns in smooth
muscle cells from diverse anatomical sites, and to search for
links between these characteristic gene expression patterns
and the differentiation, functional specialization, and con-
tribution to pathology of SMCs. The results show that SMCs
native to different anatomic sites have distinct, reproducible
gene expression patterns that persist through many gener-
ations of ex vivo culture in standard media, suggesting that
t h e s eS M C sc o m p r i s ed i s t i n c td ifferentiated cell types.
Similar observations have been made about ﬁbroblasts and
endothelial cells in our previous studies [21,25] and for many
other superﬁcially similar cell types, notably lymphocytes,
whose underlying diversity has emerged through molecular
characterization and has been shown to have implications for
our fundamental understanding of disease processes [70].
Thus, despite their apparent similarity in morphology and
function, many of the cell types that compose the stroma and
the vascular systems of various anatomical locations and
structures in the human body have diverse, distinct differ-
entiation programs and molecular specializations. Our results
on the diversity of ﬁbroblasts [25], endothelial cells [21],
smooth muscle cells (in this study), and blood cells [70]
highlight the unexpected large number of cell types in the
human body and emphasize the need for a better under-
standing of the ﬁne specialization of these different cell types.
The molecular and physiologic differences among super-
ﬁcially homogenous cells may help explain the variations in
the physiological behavior of cell types and provide insights
into the genetic networks that lead to regional differentiation
and to the ﬁnal local specialization of the architecture and
function of human tissues. This depth of understanding will
almost certainly have wide-reaching implications for human
biology.
Several biological themes emerged in our analysis of SMC
gene expression. First, although important common mecha-
nisms for regulating the expression of SMC lineage markers
are shared by all SMCs [3], unique differentiation programs
characteristic of SMCs at distinct anatomic sites were
reﬂected in the pervasive differences in gene expression
patterns. Several growth factors and transcription factors are
able to activate SMC differentiation programs [3]; the relative
importance and contribution of each growth or transcription
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of vascular SMC-speciﬁc genes appears to be partially
controlled by high TGF-b activity. It is known that TGF-b
can trigger SMC differentiation by activating the expression
of many SMC lineage genes [71] through the TGF-b control
elements present in their promoters [72]. During blood vessel
formation, TGF-b is the crucial molecular signal through
which endothelial cells recruit splanchnic mesoderm cells and
then induce them to differentiate into SMCs [73,74]. The
relatively high level of expression of both TGF-b and its
receptor may account for the characteristic biosynthetic
phenotype of vascular SMCs, as many genes involved in the
biosynthesis, trafﬁcking, and modiﬁcation of ECM proteins
are downstream target genes of TGF-b 27]. The preferential
expression of ligands, receptors, and other signaling compo-
nents of the TGF-b signaling pathway by vascular SMCs [75–
77] suggests that this feature of the vascular SMC expression
program might be maintained via an autocrine mechanism.
In contrast, the low level of TGF-b activity in visceral SMCs,
reﬂected in the low level of expression of TGF-b signaling
pathway–related genes, suggests that their differentiation
programs may be less reliant on TGF-b. Several visceral SMC-
speciﬁc transcription factors (such as MRF2 (also known as
ARID5B) and PBX1) possess the ability to trigger SMC
differentiation [6,9] and are likely to contribute to the
differentiation programs of these SMCs instead. This diver-
gence of SMC subtype differentiation programs and molec-
ular mechanisms has been found to account for differential
SM–major histocompatibility complex and CRP-1 (also
known as CEBPE) activation in various SMC subtypes [78,79].
Second, the anatomic site–speciﬁc differentiation of SMCs
may help explain the particular susceptibility of speciﬁc
tissues and organs to speciﬁc pathogenic processes. For
example, vascular SMCs, but not visceral SMCs, express large
sets of genes implicated in ﬁbrogenic matrix deposition,
tissue remodeling, hypoxia response, and inﬂammatory
responses. These biological processes are implicated in
pathogenesis of human diseases affecting SMCs, such as
atherosclerosis, hypertension, and asthma. For example, the
unique vulnerability of arterial SMCs to atherosclerosis may
be related in part to the high levels at which they express
TGF-b and the inﬂammatory response genes (Figure 3B), and
the relatively low expression level of a group of genes
involved in glutathione biosynthesis in vascular SMCs might
contribute to their relative vulnerability to damage from
oxidative stress [80].
Most patients with pulmonary artery hypertension have
elevated EDN1 levels, and pharmacological blockage of EDN1
activity leads to clinical improvement and better prognosis
[81]. EDN1 receptor A mediates a contractile response to
EDN1 in SMCs; the high intrinsic expression of its transcript
in pulmonary artery SMCs suggests that pulmonary arteries
may be especially sensitive to the vasoconstrictive activity of
circulating EDN1 [82]. The differential expression of ﬁbrillin
1 and ﬁbrillin 2 in SMCs may be related to the anatomic
speciﬁcity of diseases that result from defects of these
proteins. Fibrillin 1 is expressed exclusively in vascular SMCs
while ﬁbrillin 2 is found also in colon SMCs (Figure 2B).
Mutations in ﬁbrillin 1 lead to Marfan’s syndrome, in which
major defects affect the vascular structures, in agreement
with vascular SMC expression of ﬁbrillin-1 (Figure 2B).
Mutations in ﬁbrillin 2, on the other hand, lead to congenital
contractural arachnodactyly. In addition to vascular defects,
congenital contractural arachnodactyly patients suffer from
abnormalities in the digestive tract, such as duodenal atresia,
esophageal atresia, and intestinal malrotation [83]. Thus, links
between differential gene expression and disease phenotypes
may provide a basis for the localization of defects in
syndromes, paralleling similar ﬁndings in ﬁbroblasts [25].
Third, specialized gene expression programs reﬂecting
anatomically speciﬁc differentiation may underlie the dis-
tinct mechanical properties of the SMCs in each tissue. For
example, uterine SMCs express genes encoding contractile
proteins and sarcomere units at especially high levels, but
cervical SMCs, while otherwise very similar, do not. The
uterus-speciﬁc expression pattern may be related to the
uterus’ unique need to generate contractile force during
parturition and points to a uterus-speciﬁc mechanism for
ﬁne tuning expression of genes broadly expressed by cells of
SMC lineage. Although SRF/myocardin levels are similar in all
SMCs, variations in the expression levels of other regulators
may account for these ﬁne-tuned differences. For example,
the oxytocin receptor, expressed primarily in uterus SMCs,
may play such a role, given its ability to trigger muscle
differentiation programs [84].
Fourth, variations in gene expression patterns suggest
regulatory mechanisms underlying position-speciﬁc differ-
entiation. For example, the patterns of expression of a small
number of HOX genes can recapitulate the same anatomic
clustering of SMCs that was originally achieved with all of the
genes in our study, suggesting that positional information
encoded in the pattern of expression of the HOX genes may
play an important role in determining the distinct molecular
phenotypes of SMCs at different sites. The expression of the
BMP4 and LIF/OSM receptor in urinary tract SMCs may be a
vestige of their developmental origins and suggests the
possibility that these cells may retain some of the devel-
opmental plasticity of their progenitors. Corollary to all of
our ﬁndings on differential gene expression in SMCs is the
idea that topographically regulated genes, which can be
studied ex vivo in cultured cells, may provide an excellent
starting point for dissecting the molecular pathways involved
in the development of individual tissues and organs.
Finally, we have found that a gene in vitro expression
program elicited in vascular SMCs by short-term exposure to
serum, an in vitro model of vascular injury [3], is predictive of
elevated risk of progression in a variety of human carcino-
mas. Expression of the vascular SMC serum-response pro-
gram in human carcinomas may reﬂect aberrant properties
of the tumor vasculature, which can often have biochemical,
structural, and compositional abnormalities that result in
defective and leaky endothelial cells. Consistent with this
possibility, tumors with a gene expression pattern resembling
the SMC serum response tend to also exhibit a strong hypoxia
response [36], another characteristic of tumors with defective
tumor vasculature [19,85]. Such vascular dysfunction may
impede drug delivery and create tumor microenvironments
that favor metastasis. The possibility that the SMC serum-
response signature could identify patients with defective
tumor blood vessels, who might beneﬁt from the emerging
cancer therapeutics that target tumor vasculature (e.g., the
VEGF-speciﬁc antibody, bevacizumab), deserves further
investigation [19,86,87].
The functional and regulatory specializations revealed by
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tissues are of particular clinical importance because SMCs are
among the cells most frequently targeted by drugs—e.g., for
the reduction of airway resistance, the regulation of blood
pressure, or for the induction or inhibition of peristalsis,
urination, or labor. Most current treatments affect SMCs
indirectly through the autonomic nervous system, and these
treatments sometimes have undesirable off-target side effects.
Perhaps more speciﬁc interventions, with fewer side effects,
might be achieved by directly targeting the intended smooth
muscle groups. A notable example of such a speciﬁcally
targeted treatment is provided by the use of oxytocin to
induce uterine contraction, by targeting the oxytocin
receptor, whose expression in smooth muscle is largely
limited to the uterus. Although this study provides only an
initial survey of the molecular diversity and heterogeneity of
SMCs, it is clear that the genes encoding many potentially
‘‘drugable’’ targets—ion channels, adhesion molecules, and
G-protein signaling receptors—are selectively expressed in
different SMCs. This fact makes them particularly interesting
as potential targets for cell type–speciﬁc therapeutics. A more
comprehensive study of global expression patterns in
anatomically distinct SMCs is likely to uncover additional
potential targets for selective SMC-directed therapeutics.
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Figure S1. Gene Expression Program of Serum Responses of
Fibroblasts and Smooth Muscle Cells
(A, B) Hierarchical clustering of a total of 1,866 elements that display
a greater than 3-fold change in mRNA expression in more than one
sample when ﬁbroblasts and SMCs are exposed to serum. The
triangles represent the time course of the indicated cell types.
Identiﬁed clusters of genes with unique expression patterns are
marked by vertical bars and expanded in (B) with the names of
representative genes shown on the right.
Found at doi:10.1371/journal.pgen.0030164.sg001 (1.3 MB PDF).
Figure S2. A Scatter Plot Showing the Relationship between the
Hypoxia-Response [36] and the SMC Serum-Response Signatures in
the Stanford Breast Cancer Dataset [68]
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